关于孕期使用加巴喷丁诺及其对妊娠和儿童结局影响的系统性综述:ConcePTION 研究。

IF 2.2 4区 医学 Q3 PHARMACOLOGY & PHARMACY Therapie Pub Date : 2024-10-18 DOI:10.1016/j.therap.2024.10.049
Anna-Belle Beau, Jingping Mo, Xavier Moisset, Justine Bénévent, Christine Damase-Michel
{"title":"关于孕期使用加巴喷丁诺及其对妊娠和儿童结局影响的系统性综述:ConcePTION 研究。","authors":"Anna-Belle Beau, Jingping Mo, Xavier Moisset, Justine Bénévent, Christine Damase-Michel","doi":"10.1016/j.therap.2024.10.049","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>In the general population, there has been a noticeable rise in the dispensing of gabapentinoids in recent years. The aim of this study was to provide an overview of all available data on the use and safety of gabapentinoids during pregnancy.</p><p><strong>Methods: </strong>A systematic review was performed in PubMed and Reprotox using the search terms: \"gabapentin\", \"pregabalin\", \"antiepileptic drugs\" and terms associated with pregnancy. We included all studies in English that reported on the use and safety of gabapentin and pregabalin during pregnancy. We excluded abstracts, literature reviews, case reports and studies involving fewer than 5 exposures. Descriptive analyses and narrative syntheses were performed.</p><p><strong>Results: </strong>A total of 27 high-quality studies were described. The prevalence of gabapentinoid use during pregnancy remained very low, at less than 1%. Five studies reported significant findings with increased risks of overall congenital anomalies, specific anomalies (nervous system, eyes, oro-facial clefs, urinary and genital system), miscarriage, stillbirth and specific neurodevelopmental outcomes after exposure to pregabalin during pregnancy. Concerning exposure to gabapentin, increased risks of preterm birth, preeclampsia, small-for-gestational-age and NICU admission were reported in two studies.</p><p><strong>Conclusions: </strong>Prenatal exposure to pregabalin is associated with an increased risk of congenital anomalies and long-term neurodevelopmental outcomes while gabapentin exposure was associated with an increased risk of preeclampsia, preterm birth and small-for-gestational age. Larger studies are needed to confirm these data and explore additional outcomes. The combined evidence from this systematic review and animal studies raises concerns about the safety of using gabapentinoids during pregnancy. Careful evaluation of the benefit-risk balance for both mother and fetus/infant is essential when these medications cannot be avoided during pregnancy.</p>","PeriodicalId":23147,"journal":{"name":"Therapie","volume":" ","pages":""},"PeriodicalIF":2.2000,"publicationDate":"2024-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Systematic review of gabapentinoid use during pregnancy and its impact on pregnancy and childhood outcomes: A ConcePTION study.\",\"authors\":\"Anna-Belle Beau, Jingping Mo, Xavier Moisset, Justine Bénévent, Christine Damase-Michel\",\"doi\":\"10.1016/j.therap.2024.10.049\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>In the general population, there has been a noticeable rise in the dispensing of gabapentinoids in recent years. The aim of this study was to provide an overview of all available data on the use and safety of gabapentinoids during pregnancy.</p><p><strong>Methods: </strong>A systematic review was performed in PubMed and Reprotox using the search terms: \\\"gabapentin\\\", \\\"pregabalin\\\", \\\"antiepileptic drugs\\\" and terms associated with pregnancy. We included all studies in English that reported on the use and safety of gabapentin and pregabalin during pregnancy. We excluded abstracts, literature reviews, case reports and studies involving fewer than 5 exposures. Descriptive analyses and narrative syntheses were performed.</p><p><strong>Results: </strong>A total of 27 high-quality studies were described. The prevalence of gabapentinoid use during pregnancy remained very low, at less than 1%. Five studies reported significant findings with increased risks of overall congenital anomalies, specific anomalies (nervous system, eyes, oro-facial clefs, urinary and genital system), miscarriage, stillbirth and specific neurodevelopmental outcomes after exposure to pregabalin during pregnancy. Concerning exposure to gabapentin, increased risks of preterm birth, preeclampsia, small-for-gestational-age and NICU admission were reported in two studies.</p><p><strong>Conclusions: </strong>Prenatal exposure to pregabalin is associated with an increased risk of congenital anomalies and long-term neurodevelopmental outcomes while gabapentin exposure was associated with an increased risk of preeclampsia, preterm birth and small-for-gestational age. Larger studies are needed to confirm these data and explore additional outcomes. The combined evidence from this systematic review and animal studies raises concerns about the safety of using gabapentinoids during pregnancy. Careful evaluation of the benefit-risk balance for both mother and fetus/infant is essential when these medications cannot be avoided during pregnancy.</p>\",\"PeriodicalId\":23147,\"journal\":{\"name\":\"Therapie\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":2.2000,\"publicationDate\":\"2024-10-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Therapie\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.therap.2024.10.049\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapie","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.therap.2024.10.049","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

摘要

目的:在普通人群中,近年来加巴喷丁类药物的配药量明显增加。本研究旨在概述有关妊娠期使用加巴喷丁类药物及其安全性的所有可用数据:方法:在 PubMed 和 Reprotox 上进行了系统性综述,搜索关键词为方法:我们在 PubMed 和 Reprotox 上进行了系统性综述,使用的检索词包括:"加巴喷丁"、"普瑞巴林"、"抗癫痫药物 "以及与妊娠相关的术语。我们纳入了所有报道孕期使用加巴喷丁和普瑞巴林的安全性的英文研究。我们排除了摘要、文献综述、病例报告和涉及少于 5 次暴露的研究。我们进行了描述性分析和叙述性综述:结果:共对 27 项高质量的研究进行了描述。孕期使用加巴喷丁诺类药物的发生率仍然很低,不到 1%。五项研究报告了重大发现,即孕期接触普瑞巴林后,总体先天畸形、特定畸形(神经系统、眼睛、口腔裂、泌尿和生殖系统)、流产、死产和特定神经发育结果的风险增加。关于暴露于加巴喷丁,有两项研究报告了早产、子痫前期、小于胎龄和入住新生儿重症监护室的风险增加:结论:产前暴露于普瑞巴林与先天性畸形和长期神经发育结果的风险增加有关,而暴露于加巴喷丁与子痫前期、早产和胎龄小的风险增加有关。需要进行更大规模的研究来确认这些数据并探讨其他结果。综合本系统综述和动物实验的证据,我们对孕期使用加巴喷丁类药物的安全性表示担忧。当妊娠期间无法避免使用这些药物时,必须仔细评估母亲和胎儿/婴儿的获益与风险之间的平衡。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Systematic review of gabapentinoid use during pregnancy and its impact on pregnancy and childhood outcomes: A ConcePTION study.

Objective: In the general population, there has been a noticeable rise in the dispensing of gabapentinoids in recent years. The aim of this study was to provide an overview of all available data on the use and safety of gabapentinoids during pregnancy.

Methods: A systematic review was performed in PubMed and Reprotox using the search terms: "gabapentin", "pregabalin", "antiepileptic drugs" and terms associated with pregnancy. We included all studies in English that reported on the use and safety of gabapentin and pregabalin during pregnancy. We excluded abstracts, literature reviews, case reports and studies involving fewer than 5 exposures. Descriptive analyses and narrative syntheses were performed.

Results: A total of 27 high-quality studies were described. The prevalence of gabapentinoid use during pregnancy remained very low, at less than 1%. Five studies reported significant findings with increased risks of overall congenital anomalies, specific anomalies (nervous system, eyes, oro-facial clefs, urinary and genital system), miscarriage, stillbirth and specific neurodevelopmental outcomes after exposure to pregabalin during pregnancy. Concerning exposure to gabapentin, increased risks of preterm birth, preeclampsia, small-for-gestational-age and NICU admission were reported in two studies.

Conclusions: Prenatal exposure to pregabalin is associated with an increased risk of congenital anomalies and long-term neurodevelopmental outcomes while gabapentin exposure was associated with an increased risk of preeclampsia, preterm birth and small-for-gestational age. Larger studies are needed to confirm these data and explore additional outcomes. The combined evidence from this systematic review and animal studies raises concerns about the safety of using gabapentinoids during pregnancy. Careful evaluation of the benefit-risk balance for both mother and fetus/infant is essential when these medications cannot be avoided during pregnancy.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Therapie
Therapie 医学-药学
CiteScore
3.50
自引率
7.70%
发文量
132
审稿时长
57 days
期刊介绍: Thérapie is a peer-reviewed journal devoted to Clinical Pharmacology, Therapeutics, Pharmacokinetics, Pharmacovigilance, Addictovigilance, Social Pharmacology, Pharmacoepidemiology, Pharmacoeconomics and Evidence-Based-Medicine. Thérapie publishes in French or in English original articles, general reviews, letters to the editor reporting original findings, correspondence relating to articles or letters published in the Journal, short articles, editorials on up-to-date topics, Pharmacovigilance or Addictovigilance reports that follow the French "guidelines" concerning good practice in pharmacovigilance publications. The journal also publishes thematic issues on topical subject. The journal is indexed in the main international data bases and notably in: Biosis Previews/Biological Abstracts, Embase/Excerpta Medica, Medline/Index Medicus, Science Citation Index.
期刊最新文献
[Over-the-counter non-steroidal anti-inflammatory medications: Focus on the management of acute pain]. DRAMES and DTA databases: Complementary tools to monitor drug-related deaths in France. Inputs of pharmacoepidemiology in addictovigilance: How do they fit together? The contribution of addictovigilance data to the French medical cannabis experimentation. Attentes méthodologiques pour la démonstration de l’efficacité des produits de santé par les études observationnelles.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1